Serum fibroblast growth factor 21 in human obesity: Regulation by insulin infusion and relationship with glucose and lipid oxidation

International Journal of Obesity

Volumn 37, Issue 10, 2013, Pages 1386-1390

  Straczkowski M ^a,b   Karczewska Kupczewska, M ^a,b   Adamska, A ^a   Otziomek, E ^a   Kowalska, I ^a   Nikolajuk A ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

Author keywords

fibroblast growth factor 21; insulin sensitivity; metabolic flexibility

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINEMIA; INSULIN INFUSION; INSULIN SENSITIVITY; LIPID OXIDATION; MALE; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY QUOTIENT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANIMALIA;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CALORIMETRY, INDIRECT; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; OBESITY; OXIDATION-REDUCTION; PREDICTIVE VALUE OF TESTS; THINNESS; TRIGLYCERIDES;

EID: 84885656318     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.10     Document Type: Article

References (22)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
2. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-437.
3. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R et al. FGF21 induces PGC1a and regulates carbohydrate metabolism during the adaptive starvation response. PNAS 2009; 106: 10853-10858.
4. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al. Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425.
5. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 25-259.
6. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
7. Chavez AO, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542-1546.
8. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 65-68.
9. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
10. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and g-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94: 2151-2156.
11. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789.
12. Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012; 153: 69-80.
13. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of insulin-sensitizing fibroblast growth factor 21. Diabetes 2009; 58: 1532-1538.
14. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T et al. Fibroblastgrowth factor 21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009; 58: 2797-2801.
15. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol 2009; 71: 369-375.
16. Vienberg SG, Brons C, Nilsson E, Astrup A, Vaag A, Andersen B. Impact of shortterm high-fat feeding and insulin-stimulated FGF21 in subjects with low birth weight and controls. Eur J Endocrinol 2012; 167: 49-57.
17. Mai K, Bobbert T, Groth C, Assmann A, Meinus S, Kraatz J et al. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol 2010; 299: E126-E130.
18. Yang M, Dong J, Liu H, Li L, Yang G. Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE 2011; 6: e26359.
19. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 2005; 115: 1699-1702.
20. Karczewska-Kupczewska M, Kowalska I, Nikoajuk A, Adamska A, Zielińska M, Kamińska N et al. Circulating brain-derived neurotrophic factor concentration is downregulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes Care 2012; 35: 358-362.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
22. Karczewska-Kupczewska M, Stŗaczkowski M, Adamska A, Nikoajuk A, Otziomek E, Górska M et al. Insulin sensitivity, metabolic flexibility, and serum adiponectin concentration in women with anorexia nervosa. Metabolism 2010; 59: 473-477.